Lutetium Lu 177 Dotatate Clinical Trials
8 actively recruiting trials across 6 locations
Also known as: 177 Lu-DOTA-TATE, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, 437608-50-9, Lutathera, Lutetium (177Lu) Oxodotreotide, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate +8 more
Pipeline
Top Sponsors
- National Cancer Institute (NCI)4
- Weill Medical College of Cornell University1
- Vanderbilt-Ingram Cancer Center1
- Mayo Clinic1
- Emory University1
Indications
- Cancer8
- Unresectable Digestive System Neuroendocrine Tumor G22
- Unresectable Digestive System Neuroendocrine Tumor G12
- Unresectable Digestive System Neuroendocrine Neoplasm1
- Digestive System Neuroendocrine Tumor1
Birmingham, Alabama2 trials
University of Alabama at Birmingham Cancer Center
University of Alabama at Birmingham Cancer Center
Duarte, California2 trials
City of Hope Comprehensive Cancer Center
City of Hope Comprehensive Cancer Center
Atlanta, Georgia1 trial
Emory University Hospital Midtown
Iowa City, Iowa1 trial
University of Iowa Hospitals and Clinics
Rochester, Minnesota1 trial
Mayo Clinic in Rochester
Nashville, Tennessee1 trial
Vanderbilt University/Ingram Cancer Center
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.